Gerard Meca retweeted
🎯 Per primera vegada, el #CLÍNIC ha tractat un tumor renal amb una sola sessió de radioteràpia d'alta precisió.
🩺 L'equip d'Oncologia Radioteràpica, integrat al Clínic Barcelona Comprehensive Cancer Centre (4CB), ha aplicat aquesta tècnica, la SBRT, a un pacient amb càncer de ronyó que no podia operar-se.
🏥 És un tractament no invasiu i ambulatori, i es va fer a la seu de Granollers, a prop de casa del pacient.
👉 f.mtr.cool/8a0o0a7j54
#4CB #CàncerDeRonyó #Radioteràpia
Gerard Meca retweeted
Spain’s high-speed network, the world’s longest after China’s, was once a source of national pride. Now Spaniards are in shock economist.com/europe/2026/10…
Gerard Meca retweeted
New #URONCOR0624 publication!
Low early adverse events and preserved quality of life after salvage RT + ADT.
340/534 patients enrolled. Thanks to all patients and investigators!
🔗 ctro.science/article/S2405-6…
🎯 100% Local Control & 100% Cancer-Specific Survival. Long-term results of the FASTRACK II trial primary #kidneycancer.
✅ No local failures or cancer deaths
✅ Safe for high-risk/inoperable patients
✅ Kidney function preserved long-term
#ESTRO26 #RadOnc #SABR @_ShankarSiva
Gerard Meca retweeted
#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm
1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
2) 100% Cancer-Specific Survival
3) Grade 3 AEs remain at 10%
Gerard Meca retweeted
Our “Best of” #ESTRO26 outline is now live! 🚀
What key studies are we missing?
Drop any important trials, abstracts, or presentations we should add 👇
bit.ly/BestOfESTRO2026
#RadOnc #ESTRO26 #ESTRO2026
Gerard Meca retweeted
Avui hem tancat quatre dies intensos d’auditoria del projecte #CATClinART EU4Health @hospitalclinic
Gràcies als auditors per la mirada experta i a l’equip OR per la implicació i l’esforç. Ha estat una experiència d’aprenentatge molt valuosa que ens ajuda a continuar millorant.
Gerard Meca retweeted
Here is Version 2.0 of when to hold systemic tx during RT. Updated & w 3 additional drug categories (ADCs, CDK4/6 inhibitors, PARPi).
More details on newer drugs in 🧵 below.
Please use this version as reference & thanks for all input/experience crowdsourcing! (1/3)
Gerard Meca retweeted
PSA is NOT enough. ⚠️
Radiographic progression can happen without PSA rise on enzalutamide.
New JCO analysis from ARCHES + PROSPER 👇
🧬 Study population
•mHSPC (ARCHES)
•nmCRPC (PROSPER)
•Enzalutamide ± ADT
•n = 2,551
💡 Key finding
➡️ PSA and imaging can be discordant
📊 What’s striking?
•~22–25% → rPD with no PSA rise
•~51–62% → no PSA progression despite rPD
•Even undetectable PSA at progression seen
📍 Liver mets more common with enzalutamide
⚠️ Prognosis
➡️ rPD = worse OS
➡️ Regardless of PSA behavior
🧠 Clinical implication
👉 PSA alone can MISS progression
👉 Imaging must NOT be delayed
📌 Practice-changing takeaway
➡️ Do periodic imaging even if PSA is stable
Because cancer doesn’t always follow PSA.
📖 Full paper in comment ⬇️
#OncoTwitter #MedTwitter #ProstateCancer #UroOnc
@oncoalert @asco
Gerard Meca retweeted
Fantastic news for renal cancer patients. Latest NICE guideline recommends #SABR to primary RCC for selected patients with stage IA and IB disease! nice.org.uk/guidance/ng256/r… #radonc #medonc #SBRT
Big thanks to @_ShankarSiva who has pioneered this important treatment option
Gerard Meca retweeted
#EAU26 DRE not recommended for asymptomatic men. I could not agree more in era of MRI.
PRostate cancer guidelines 2026 update. Digital rectal exam NOW no more recommended for Asymptomatic men
SO NO MORE FOR Screening
Important for standing and for early diagnosis for SYMPTOMS only @Uroweb
Gerard Meca retweeted
🚀 Largest prospective SABR cohort in inoperable RCC. Pooled FASTRACK trials show 98% local control at 5 years, excellent CSS, low ≥G3 toxicity and no late safety signals. A durable, non‑invasive, kidney‑sparing option—now poised for randomized comparison vs surgery. #EAU26
Gerard Meca retweeted
This is our work. It’s the published series with the longest follow up. Moderate hypofractionation seems complety safe, and actually the highest toxicity profile for now seems with normofractionation at longest FU
link.springer.com/article/10…
Gerard Meca retweeted
🚨 New publication
🇪🇸 National SEOR-GI survey on Total Neoadjuvant Therapy (TNT) in locally advanced rectal cancer, now in Clinical and Translational Oncology.
👏 Congrats to Sigfredo Romero, coordinator of the SEOR GI Tumors Group.
🔗 rdcu.be/e6Qfl
#RectalCancer
Gerard Meca retweeted
🔴Online now: Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised #prostatecancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
thelancet.com/journals/lanon…
Gerard Meca retweeted
🔴El Dr. Mariano Barbacid y su equipo, financiados por #CRISContraelCáncer, han logrado curar el cáncer de páncreas en ratones, de forma duradera y sin efectos secundarios.
Pero necesitamos tu ayuda para que esto sea una realidad en pacientes.
DONA AQUÍ👉ow.ly/b5cA50Y6Ou7
Gerard Meca retweeted
Since the sudden PSA elevation didn’t make sense, we were concerned about a spurious PSA result which could be due to interfering heterophilic antibodies (pubmed.ncbi.nlm.nih.gov/2210…).
Gerard Meca retweeted
Any idea of the denominator for the study, ie how many patients these 20 centres treated with radiotherapy over the preceding few years? That would help me understand the impact of this work.
💉 Liquid biopsy in #radiotherapy?
Tracking tumour #DNA in blood could let doctors adapt radiation therapy in real time — making treatment truly personalised.
👉 bit.ly/3NSWQj3
#biology









































